Company Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer.
Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring.
The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University.
Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
| Country | United States |
| Founded | 1995 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 7,000 |
| CEO | Kevin Conroy |
Contact Details
Address: 5505 Endeavor Lane Madison, Wisconsin 53719 United States | |
| Phone | 608 284 5700 |
| Website | exactsciences.com |
Stock Details
| Ticker Symbol | EXAS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001124140 |
| CUSIP Number | 30063P105 |
| ISIN Number | US30063P1057 |
| Employer ID | 20-4782291 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Kevin T. Conroy J.D. | Chairman of the Board and Chief Executive Officer |
| Aaron Bloomer | Chief Financial Officer |
| Sarah Condella | Executive Vice President of Human Resources |
| Jacob Orville MBA | Executive Vice President and GM of Screening |
| Brian Baranick | Executive Vice President and General Manager of Precision Oncology |
| Dr. Jorge A. Garces Ph.D. | Chief Science Officer |
| Nassar Nizami | Chief Information Officer |
| Derek Leckow | Vice President of Investor Relations |
| James Herriott | Senior Vice President, General Counsel and Secretary |
| Graham P. Lidgard Ph.D. | Emeritus Chief Science Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 1, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2025 | 8-K | Current Report |
| Feb 19, 2025 | 10-K | Annual Report |
| Feb 19, 2025 | 8-K | Current Report |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |